Philip R - Search Results

1

Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.

Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, Krakover J, Secord AA, Clay TM, Morse MA, Dubensky TW Jr, Brockstedt DG, Philip R, Giedlin M. Sinnathamby G, et al. Among authors: philip r. J Immunother. 2009 Oct;32(8):856-69. doi: 10.1097/CJI.0b013e3181b0b125. J Immunother. 2009. PMID: 19752748

2

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.

Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A, Secord AA, Lyerly HK, Morse MA, Philip R. Sinnathamby G, et al. Among authors: philip r. Clin Exp Immunol. 2011 Mar;163(3):324-32. doi: 10.1111/j.1365-2249.2010.04298.x. Epub 2010 Dec 22. Clin Exp Immunol. 2011. PMID: 21175594 Free PMC article.

3

Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.

Philip R, Murthy S, Krakover J, Sinnathamby G, Zerfass J, Keller L, Philip M. Philip R, et al. Among authors: philip m. J Proteome Res. 2007 Jul;6(7):2509-17. doi: 10.1021/pr0606777. Epub 2007 Jun 5. J Proteome Res. 2007. PMID: 17547437 Free PMC article.

4

A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.

Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M. Karkada M, et al. Among authors: philip r. J Immunother. 2010 Apr;33(3):250-61. doi: 10.1097/CJI.0b013e3181c1f1e9. J Immunother. 2010. PMID: 20445345

5

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R. Morse MA, et al. Among authors: philip m, philip r. Clin Cancer Res. 2011 May 15;17(10):3408-19. doi: 10.1158/1078-0432.CCR-10-2614. Epub 2011 Feb 7. Clin Cancer Res. 2011. PMID: 21300761 Clinical Trial.

6

MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.

Shetty V, Sinnathamby G, Nickens Z, Shah P, Hafner J, Mariello L, Kamal S, Vlahović G, Lyerly HK, Morse MA, Philip R. Shetty V, et al. Among authors: philip r. J Proteomics. 2011 May 1;74(5):728-43. doi: 10.1016/j.jprot.2011.02.020. Epub 2011 Mar 11. J Proteomics. 2011. PMID: 21362506

7

Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells.

Shetty V, Nickens Z, Testa J, Hafner J, Sinnathamby G, Philip R. Shetty V, et al. Among authors: philip r. J Proteomics. 2012 Jun 18;75(11):3270-90. doi: 10.1016/j.jprot.2012.03.044. Epub 2012 Apr 3. J Proteomics. 2012. PMID: 22504797

8

Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Karabudak AA, Hafner J, Shetty V, Chen S, Secord AA, Morse MA, Philip R. Karabudak AA, et al. Among authors: philip r. J Cancer Res Clin Oncol. 2013 Oct;139(10):1757-70. doi: 10.1007/s00432-013-1501-6. Epub 2013 Sep 3. J Cancer Res Clin Oncol. 2013. PMID: 23999876 Free PMC article.

9

Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.

Comber JD, Karabudak A, Huang X, Piazza PA, Marques ET, Philip R. Comber JD, et al. Among authors: philip r. Hum Vaccin Immunother. 2014;10(12):3531-43. doi: 10.4161/21645515.2014.980210. Hum Vaccin Immunother. 2014. PMID: 25668665 Free PMC article.

10

A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles.

Huang X, Karabudak A, Comber JD, Philip M, Morcol T, Philip R. Huang X, et al. Among authors: philip m, philip r. Hum Vaccin Immunother. 2017 Nov 2;13(11):2612-2625. doi: 10.1080/21645515.2017.1369639. Epub 2017 Sep 21. Hum Vaccin Immunother. 2017. PMID: 28933657 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

612 results

Search Page